Neuropex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.58 M
About Neuropex Pharmaceuticals
Neuropex Pharmaceuticals Private Limited (NPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 09 December 2019 (Five years and two months 22 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.58 M.
Ajay Mishra, Neha Agarwal, and Rohit Khanna serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U51900UP2019PTC124277
- Company No.
124277
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Pharma
What products or services does Neuropex Pharmaceuticals Private Limited offer?
Neuropex Pharmaceuticals Private Limited offers a wide range of products and services, including Vitamins & Supplements, Vitamins A-Z.
Who are the key members and board of directors at Neuropex Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Khanna  | Director | 09-Dec-2019 | Current |
| Ajay Mishra | Director | 09-Dec-2019 | Current |
| Neha Agarwal | Director | 09-Dec-2019 | Current |
Financial Performance of Neuropex Pharmaceuticals.
Neuropex Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Neuropex Pharmaceuticals?
In 2020, Neuropex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹1.58 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.16 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Sep 2024 | Axis Bank Limited | ₹1.58 M | Open |
How Many Employees Work at Neuropex Pharmaceuticals?
Neuropex Pharmaceuticals has a workforce of 11 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuropex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuropex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.